Bristol Myers Squibb (BMY) Income from Discontinued Operations (2009)
Bristol Myers Squibb's (BMY) quarterly Income from Discontinued Operations came in at $7.2 billion in Q4 2009, up 4401.26% quarter-over-quarter from $159.0 million in Q3 2009.
Powered by 
Analysis
Bristol Myers Squibb (BMY) Income from Discontinued Operations (2009) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Income from Discontinued Operations for 1 consecutive years, with $7.2 billion the latest figure, recorded in Q4 2009.
- On a quarterly basis, Income from Discontinued Operations changed N/A year-over-year to $7.2 billion in Q4 2009; TTM through Dec 2009 was $7.4 billion, a N/A change from a year earlier, with the FY2009 full-year figure at $7.4 billion, changed N/A from the prior year.
- Income from Discontinued Operations was $7.2 billion for Q4 2009 at Bristol Myers Squibb, up from $159.0 million in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at $7.2 billion in Q4 2009 and troughed at -$11.0 million in Q1 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 8.00 Mn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2009 | 7.16 Bn |
| Sep 30, 2009 | 159.00 Mn |
| Jun 30, 2009 | 129.00 Mn |
| Mar 31, 2009 | -11.00 Mn |